We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Orexigen Struggles as Contrave Commercialization Costs Rise
Read MoreHide Full Article
On Jan 3, we issued an updated research report on Orexigen Therapeutics, Inc. . This biopharmaceutical company, based in La Jolla, CA, is focused on the development of obesity treatments.
In the last three months, Orexigen’s share price has underperformed the industry to which it belongs to. The stock has lost 40.4% compared with a decrease of 7% for the industry.
We remind investors that Orexigen had terminated its collaboration agreement with Takeda for commercializing Contrave in the United States in early 2016 and started selling the drug itself. Sales numbers improved in three quarters of 2017 as the company booked product sales in the United States instead of royalties paid by Takeda on Contrave sales in the United States in the year-ago period. However, the increase in revenues was offset by costs associated with commercializing of the drug which resulted in losses in 2017.
The estimate revision trend for the fourth quarter of 2017 remains unfavorable with one estimate moving down and no revisions in the opposite direction in the past 60 days. Estimates declined 5.1% from a loss of $1.96 per share over this period to a loss of $2.06 per share. The trend reflects analyst apprehensions over the stock’s performance in the fourth quarter.
Contrave is Orexigen’s only approved and marketed drug. But Contrave is a late entrant in the obesity market already crowded with products like VIVUS, Inc.’s Qsymia, Novo Nordisk’s (NVO - Free Report) Saxenda and Arena Pharmaceuticals, Inc.’s Belviq.
However, the targeted sales efforts to drive Contrave sales are a positive as prescriptions and sales have risen sequentially in 2017. Moreover, low rates of penetration and awareness and the lack of safe and effective treatment options make the obesity market highly lucrative.
The company is also collaborating with regional partners in Europe for expansion.
Meanwhile, a ruling from the United States District Court for the District of Delaware has confirmed the exclusivity of Contrave through 2030.
But the absence of any late stage pipeline candidate is concerning. If Contrave disappoints, the company will have little to fall back on. Execution risks remain even though Orexigen continues to work on growing Contrave sales in the United States.
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It’s a once-in-a-generation opportunity to invest in pure genius.
Image: Bigstock
Orexigen Struggles as Contrave Commercialization Costs Rise
On Jan 3, we issued an updated research report on Orexigen Therapeutics, Inc. . This biopharmaceutical company, based in La Jolla, CA, is focused on the development of obesity treatments.
In the last three months, Orexigen’s share price has underperformed the industry to which it belongs to. The stock has lost 40.4% compared with a decrease of 7% for the industry.
We remind investors that Orexigen had terminated its collaboration agreement with Takeda for commercializing Contrave in the United States in early 2016 and started selling the drug itself. Sales numbers improved in three quarters of 2017 as the company booked product sales in the United States instead of royalties paid by Takeda on Contrave sales in the United States in the year-ago period. However, the increase in revenues was offset by costs associated with commercializing of the drug which resulted in losses in 2017.
The estimate revision trend for the fourth quarter of 2017 remains unfavorable with one estimate moving down and no revisions in the opposite direction in the past 60 days. Estimates declined 5.1% from a loss of $1.96 per share over this period to a loss of $2.06 per share. The trend reflects analyst apprehensions over the stock’s performance in the fourth quarter.
Contrave is Orexigen’s only approved and marketed drug. But Contrave is a late entrant in the obesity market already crowded with products like VIVUS, Inc.’s Qsymia, Novo Nordisk’s (NVO - Free Report) Saxenda and Arena Pharmaceuticals, Inc.’s Belviq.
However, the targeted sales efforts to drive Contrave sales are a positive as prescriptions and sales have risen sequentially in 2017. Moreover, low rates of penetration and awareness and the lack of safe and effective treatment options make the obesity market highly lucrative.
The company is also collaborating with regional partners in Europe for expansion.
Meanwhile, a ruling from the United States District Court for the District of Delaware has confirmed the exclusivity of Contrave through 2030.
But the absence of any late stage pipeline candidate is concerning. If Contrave disappoints, the company will have little to fall back on. Execution risks remain even though Orexigen continues to work on growing Contrave sales in the United States.
Orexigen Therapeutics, Inc. Price
Orexigen Therapeutics, Inc. Price | Orexigen Therapeutics, Inc. Quote
Orexigen has a Zacks Rank #4 (Sell).
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Wall Street’s Next Amazon
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It’s a once-in-a-generation opportunity to invest in pure genius.
Click for details >>